AzTrials
AzTrials

Musculoskeletal PainPhase 1NCT00823147

Pain Catastrophizing as a Cause for Systemic Inflammation

A Phase 1 study testing Pain Catastrophizing Induction in people with Musculoskeletal Pain, run by Beth Darnall, PhD at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Research shows that the immune system is involved in chronic pain. The immune system is involved in the process of inflammation. The investigators are still learning about the factors that cause inflammation, but know it can be measured in the blood. Read more about this study

Who is it for?
Ages 18 to 70 years, women only
Conditions the study is for
Musculoskeletal Pain
What is being tested?
Pain Catastrophizing Induction
Could I receive a placebo?
No, everyone receives an active treatment
How many people
93 participants
Where
1 siteUnited States
Study dates
Jan 2009to Sep 2014
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Women between the ages 18-70
  • Non-smokers
  • Diagnosed with musculoskeletal chronic pain
  • Normal menstrual cycle or postmenopausal

Who cannot join

  • Psychosis or suicidality
  • Current Major Depression
  • Former intravenous drug user
  • Needle/blood/injection phobia
  • Limited venous access
  • Sex-steroid dysregulation
Show all 11Show fewer
  • Self-Reported Pregnancy
  • Fibromyalgia or inflammatory disease, e.g. lupus
  • Active corticosteroid regimen
  • Taking beta blockers
  • Taking oral contraception or hormone therapy

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Oregon Health and Science Universtiy

    Portland, Oregon, 97239

Other trials in United States

About this study

Research shows that the immune system is involved in chronic pain. The immune system is involved in the process of inflammation. The investigators are still learning about the factors that cause inflammation, but know it can be measured in the blood. The purpose of this study is to understand how negative thoughts affect the immune system in women with chronic pain.

A sub-study asks subjects to store a blood sample for future research by the PI aimed at identifying genetic markers in women with chronic pain.

Read the detailed description

A main goal of the study is to better understand pain mechanics. Research has linked pro-inflammatory cytokines to the development and progression of pain. Research has also linked female gender with increases in pro-inflammatory cytokines (relative to males) following psychological stress. Therefore, we hypothesize that women in the study who evidence significantly increased pro-inflammatory cytokines following pain catastrophizing may be at risk for the progression of their pain condition.

The sample will be 60 women having chronic musculoskeletal pain (we will enroll up to 75 persons to account for attrition and screen failures but require the usable data of only 60 women). Based on enrollment rates for our previous study, and given our expanded catchment area, we expect to enroll 60 persons within approximately 14 months and to complete the experimental phase of the study within approximately 17 months. The follow-up phase of the study will continue, for as long as participants agree to be followed for up to 10 years.

The study design is a randomized, controlled experiment. Participants are consented and enrolled under the impression that they will undergo one stress experiment day (lasting about 5.5 hours). However, on their study day we will randomize subjects to either be in the control group or the catastrophizing (stress) group.

Screening Visit: The purpose of this visit is to determine eligibility and obtain informed consent. Inclusion and exclusion criteria will be assessed through medical record review, a screening interview, and a hormonal bloodspot kit. A questionnaire will also be given to determine level of depressive symptoms and to assess for suicidality. The hormonal bloodspot kit involves a finger prick and obtaining about 5-6 drops of blood. If lab analysis of this kit determines abnormal hormonal levels, persons will be excluded from further participation in the study. Participants will be given a saliva kit to gather 4 saliva samples at home over the course of one day. Participants will store these saliva samples in their refrigerator. They will either bring in the kit at the time of their study visit or mail the kit in a prepaid box given to them (the hormones in the saliva are shelf stable for up to 3 weeks; we will ask participants to refrigerate the samples if they are not immediately mailing them or bringing them to the study site. In this way we will best ensure that samples will be preserved and usable). All participants enrolled in the study will be under the impression that they will be participating in a catastrophizing experiment during their study day. However, only half of the participants will actually experience the 10-minute stress experiment on experiment day. We have included this minor form of deceit in the protocol so we can control for the anticipatory stress of expecting to experience a negative emotional experiment. We highlight here that the mild deception will occur for only half the sample (those going into the control group) and it represents a decrease in risk for these persons.

Study Visit: This study visit is scheduled to occur during the follicular phase of the menstrual cycle (this phase follows the menstrual period and is easy to predict in our sample of normally menstruating women by using a calendar). If difficulty is encountered in predicting the date of the follicular phase, participants will call the PI or study coordinator when their menstrual period begins to schedule their study date (approximately 5-6 days from onset on menses). All participants arrive in a fasting state, during their follicular phase to control for sex-steroid influences on immunity. 3ml of blood will be drawn for hormone levels. The hormone level will not be analyzed at this time, but saved until the end of the study for analysis, if needed. A complete cardiometabolic panel will be measured via bloodspot. If the subject agrees to take part in the sub study, we will take an additional 10mL of blood for an extra bloodspot card that we will store for future pain/genomic research. Pain ratings will be assessed, and questionnaires will be completed. Standardized meals (with no caffeine) will be served to participants (breakfast, lunch, snacks). An OCTRI research nurse will place an intravenous catheter into the arm of participant's choosing. A Holter heart monitor will be placed on participants by nursing. This is a portable device that measures heart beat. Placement of the leads around the heart involves cleaning the skin. The monitor will remain affixed for the duration of the study visit. At this point participants will be randomized to either be in the control group or in the catastrophizing group using a random number generator. After they are randomized into one of the two groups, the deception will be revealed to the control group, and its rationale explained. Those randomized to the stress group will be informed of the deception, and the rationale for having used it, at the conclusion of the study visit .

Those in the control group will have serum measurements taken at the time points listed in the study activities table below. They will occupy themselves for the next 4.5 hours with activity options to keep them from sleeping during the study visit, such as reading magazines, crossword puzzles, or games. We will have these on hand, or they can bring them to the visit. At each time point, salivary cortisol, heart rate, blood pressure, and pain ratings will be assessed. At the end of the final blood draw, the IV catheter is removed and the first study visit is complete.

Those persons randomized to the catastrophizing group will undergo a 10min pain catastrophizing induction following the 25 min post- IV catheterization rest period (we are also calling this the stress experiment). The PI will guide participants to focus on their pain, to imagine it worsening in the near future, and to describe how their worsening pain will affect life domains most important to them. The induction is standardized in the following ways: 1) duration of induction (10 minutes); 2) imaginal focus on pain worsening in the near future; 3) participants are guided to describe the anticipated negative consequences of their pain worsening; 4) participants will be guided to describe the ways in which they feel helpless while imagining the scenario. Items 2-4 are designed to tap the 3 components of pain catastrophizing (rumination, magnification of pain, helplessness).

Pain ratings and stress response will be measured via heart rate and blood pressure and salivary cortisol according to the study activities table below. No bloodspot kits will be collected during this visit. This study visit ends after the 270min post-induction blood draw. The PI will debrief subjects and assess their affective state. Free counseling will be offered before the subject leaves the study visit (only one person in the previous study opted for the post-study counseling). If anyone in the stress group would like a counseling referral the PI will provide local options to them. All participants receive a next-day telephone call to assess for mood state and adverse events.

Long-term Follow-Up: We have included a separate consent form to allow us to follow subjects over time. A main goal of the study is to better understand pain mechanics. Research has linked pro-inflammatory cytokines to the development and progression of pain. Research has also linked female gender with increases in pro-inflammatory cytokines (relative to males) following psychological stress. Therefore, we hypothesize that women in the study who evidence significantly increased pro-inflammatory cytokines following pain catastrophizing may be at risk for the progression of their pain condition. We expect that if we follow our sample over time, we will see a trend that will serve as preliminary data to allow us to investigate this further. While the catastrophizing experiment will provide us with meaningful data, this longitudinal sub study will allow us to define the clinical and functional relevance of our findings. For those who consent to this related study, subjects will be contacted every 6 months for up to 10 years and asked several questions about their pain, mood, function, and stress levels. They will also be asked to complete 4 questionnaires including: the Oswestry Disability Index, The CES-D form, and the Perceived Stress Scale. These questionnaires can be read to the subject over the phone or completed on paper. If the subject would like to complete them on paper, an address, stamped return envelope will be provided. They will also be asked if we can contact them again in 6 months.

Being tested
Pain Catastrophizing Induction
Keywords
Pain, Systemic Inflammation, Pain Catastrophizing
Medical subject headings
Musculoskeletal Pain, Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Pain Catastrophizing InductionBehavioural

    Participants will undergo a psychologist-guided 10-minute induction of negative cognitive focus on the theoretical future worsening of one's pain condition.Biological stress response will be measured via heart rate, blood pressure and serum cortisol.

Study groups in NCT00823147
Study groupRoleWhat they receive
Pain Catastrophizing Induction GroupExperimentalCollect salivary cortisol kit if subject did not mail from home Full battery of self-report measures given. Pain ratings taken (0-10). Height and weight measured. Heart monitor affixed. Catheter placed; 25 minute rest. Catastrophizing group: 10-minute catastrophizing induction. Participants self-rate their level of emotional distress. Subsequent blood draws occur per protocol time points: 1. 25 minutes following IV placement (BASELINE) 2. 15 minutes post catastrophizing induction (stress experiment) 3. 90 minutes (1.5 hours) post-induction 4. 150 minutes (2.5 hours) post-induction 5. 210 minutes (3.5 hours) post-induction 6. 270 minutes (4.5 hours) post-induction
Receives: Behavioral: Pain Catastrophizing Induction
Control GroupNo interventionCollect salivary cortisol kit if subject did not mail from home Full battery of self-report measures given. Pain ratings taken (0-10). Height and weight measured. Heart monitor affixed. Catheter placed; 25 minute rest. Control group: Persons in this group will rest, complete puzzles, read emotionally-neutral material or watch videos provided to them. Blood draws and saliva samples gathered per protocol time points: 1. 25 minutes following IV placement (BASELINE- T1) 2. 25 minutes following baseline T2 3. 115 minutes (1 hour 55 min) post baseline T3 4. 175 minutes (2 hours 55 min) post baseline T4 5. 235 minutes (3 hours 55 min) post baseline T5 6. 295 minutes (4 hours 55 min) post baseline T6

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in pro-inflammatory cytokine levels assessed from immunoassay samples

    Measured: 3.5 hours

  2. Change in anti-inflammatory cytokine levels assessed from immunoassay samples

    Measured: 3.5 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Jan 2009 (estimated)
  2. Study startJan 2009
  3. Primary completionApr 2012
  4. Study completionSep 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Single group
Masking
Single blind
Who is masked
Participant
Enrolment
93 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00823147
Sponsor's protocol ID
4920
Other IDs
5 K12 HD04348807
Status last verified
Jul 2019
First submitted
13 Jan 2009
Last updated
6 Aug 2019
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Pain Catastrophizing Induction in people with Musculoskeletal Pain, run by Beth Darnall, PhD at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Aug 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in pro-inflammatory cytokine levels assessed from immunoassay samples (time frame: 3.5 hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2019.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in